The Peptide AppField Guide · Healing SeriesField Specimen

Healing Category

Chonluten

Name: Chonluten: Uses, Evidence & Safety
Creator: The Peptide App
Published: 2026-01-27T18:38:35.818468+00:00

THE BREATH ENHANCER

Peptide Complex AC-7

Chonluten is a synthetic tripeptide (Glu-Asp-Gly) designed to support respiratory health. It works by penetrating lung cells and modifying gene expression to restore the epithelial lining, reduce inflammation, and improve surfactant production. It's particularly useful for chronic respiratory conditions and age-related lung decline.

Chonluten

Chonluten Evidence Snapshot

How these guides are reviewed

Regulatory status: Not FDA approved · research use only
Dosing guidance: Reviewed by our clinical team
Linked evidence: 1 research sources
Content updated: May 8, 2026

Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.

Quick Answers About Chonluten

Is Chonluten FDA approved?

No. This profile records Chonluten as not FDA approved and for research use only.

More context

Review the regulatory and source details on this page for the current context.

What dose does The Peptide App Clinical Team recommend for Chonluten?

Dose: 30 mg daily (oral or subcutaneous).

More context

Schedule: daily. Cycle: 4 weeks on, 8 weeks off. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.

What research supports this Chonluten guide?

This guide links to 1 curated or current research sources.

More context

Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.

Review the Chonluten research sources

Studied Effects & Mechanisms

Gene Regulation

Modifies lung cell gene expression for tissue repair

Epithelial Repair

Restores the protective lining of airways

Anti-Inflammatory

Reduces lung inflammation and fibrotic markers

Who is this for

People with chronic respiratory conditions

Smokers or former smokers

Those recovering from lung infections

Aging individuals with declining lung function

Anyone wanting to protect lung health

Chonluten Dosing

Dosage

30 mg daily (oral or subcutaneous)

Schedule

daily

Cycle

4 weeks on, 8 weeks off

Clinical Team Note

Take in the evening after meals for best absorption

Get your exact syringe units with the reconstitution calculator

Clinical Team Dosing Guidance

Reported Timeline

Week 1-2

Nothing you'll feel yet. The peptide is starting to act on lung tissue.

Week 2-3

Reduced inflammation and easier breathing

Week 4

Improved lung function and capacity

Lung function improvements develop gradually over the treatment cycle.

Timelines summarize reported or expected patterns and are not guaranteed individual outcomes.

Clinical Safety Context

Excellent Safety

Editorial grade A · Excellent

SafetyAExcellent

FDA approval statusNo · research use only

Well-tolerated synthetic peptide with no significant side effects reported.

Works through gene expression changes. Best for long-term respiratory support.

Possible side effects

None consistently reported

How to interpret safety grades

The Peptide App

Set up your Chonluten schedule

Dose reminders and your schedule, ready the moment you open the app.

Research-Market Price Snapshot

A compact market signal for this profile. The dedicated pricing page owns vendor, vial-size, and price-per-mg comparisons.

Updated Aug 29, 2026

Vendors: 13
Listings: 13
Observed range: $32–$70

Compare all Chonluten prices →

Market evidence

Chonluten product testing and COAs

Current certificates are on file for 9 of 14 vendors tracked in the Chonluten market. Research on this page describes the molecule. Vendor certificates concern particular market samples or batches; they do not change the research evidence or establish clinical safety, sterility, or suitability for use.

View vendor COAs and pricing →Testing database How to read a COA